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Abstract 
Oral mucositis is one of the most common side effects of cancer treatment (chemotherapy and/or radiotherapy). It is 
an inflammatory process that affects the mucosa of the oral cavity, giving rise to erythematous areas in combination 
with ulcers that can reach a large size. The true importance of oral mucositis is the complications it causes – funda-
mentally intense pain associated to the oral ulcers, and the risk of overinfection. This in turn may require reduction 
or even suspension of the antineoplastic treatment, with the risk of seriously worsening the patient prognosis. This 
points to the importance of establishing therapeutic tools of use in the prevention and/or treatment of mucositis. The 
present study offers a literature review of all the articles published over the last 10 years referred to the prevention 
and/or treatment of oral mucositis associated to chemotherapy.
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Introduction
Oral mucositis (OM) is defined as inflammation of the 
mucosa oral cavity, and is clinically characterized by the 
presence of erythematous areas that subsequently merge 
with ulcerations (1).
Oral mucositis is caused by destruction of the oral muco-
sal epithelium and suppression of its growth secondary 
to antineoplastic treatment in the form of chemothera-
peutic drug substances or radiotherapy (2,3).
The pathogenesis of mucositis is currently based on a 
model comprising five biological phases, developed by 
Sonis et al. (4): initiation, signaling, signal amplifica-
tion, ulceration and healing.
The frequency of mucositis and its severity are funda-
mentally dependent upon the type, duration and dose 
of chemotherapy used (5). In this sense, bone marrow-
suppressing (myeloablative) chemotherapy is associa-
ted with a mucositis risk of 60-100% (4,6,7), while the 
combination of chemotherapy and radiotherapy implies 
a risk of almost 100% (3).
The clinical manifestations of OM become visible 4-5 
days after the start of chemotherapy, with the detection 
of erythematous areas in the oral cavity. After 7-10 days 
ulcers start to develop; these gradually grow in number 
and size, and tend to merge, forming large ulcerated zo-
nes (4,8). The ulcers are generally of scant depth, with 
a necrotic base, and the margins show little inflamma-
tory infiltration. These lesions are very painful, cause 
swallowing problems, and take about two weeks to heal 
once chemotherapy has been suspended (3,4).
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A number of OM classification and staging systems have 
been described (9), though the most widely used is that 
proposed by the World Health Organization (WHO)(Ta-
ble 1).
Results
The main strategies and drugs described in the literature 
over the last 10 years designed to prevent and/or treat 
OM secondary to chemotherapy are the following:
- Oral hygiene protocols
Oral care can reduce the presence of microbial flora, 
the pain and bleeding, and prevent infections. Likewise, 
good oral health reduces the risk of dental complications 
(6). However, the effectiveness of oral hygiene in pre-
venting the appearance of OM or in reducing its severity 
has been placed in doubt, since the studies published to 
date offer contradictory results (12,13).
- Chlorhexidine digluconate
The antimicrobial agent most widely studied in the ma-
nagement of OM is chlorhexidine, used in oral rinses at 
concentrations of 0.12-0.2%, since it has been sugges-
ted to be useful in maintaining improved oral hygiene 
and in reducing mucosal inflammation (1). However, the 
results obtained in the different clinical trials are incon-
clusive (1,2,14).
- Cytoprotective agents
• Amifostine:
Amifostine (Ethyol®) is an organic thiophosphate belie-
ved to act as a reactive oxygen species (ROS) scavenger. 
In this context, ROS are known to play a key role in the 
etiopathogenesis of OM (2,15). 
In this review we have found only one randomized, 
controlled clinical trial (RCCT) published in the last 10 
years, which reported no benefits with the preventive 
use of amifostine in patients subjected to chemotherapy- 
radiotherapy (16).
• Sucralfate:
Sucralfate is a drug with cytoprotective properties used 
in the treatment of peptic ulcers (1). Many studies have 
evaluated its effectiveness in irradiated patients, with 
very dissimilar results. In contrast, it is little used in 
patients subjected to chemotherapy. Indeed, over the 
last decade, only one RCCT has examined the effect of 
sucralfate rinses in patients subjected to chemotherapy 
with 5-fluorouracil (5-FU)(17), and its results indicate 
no effectiveness in the prevention of OM.
• Glutamine:
Glutamine is one of the most abundant amino acids 
in the body, where it is involved in numerous benefi-
cial functions. It could be of help in the prevention and 
treatment of OM, since it plays a fundamental role in 
regulation of the redox potential, and some studies have 
even suggested that it exerts a favorable effect by redu-
cing the production of proinflammatory cytokines (10).
In the last 10 years three RCCTs (18-20) have evaluated 
the preventive effects of glutamine in patients scheduled 
for chemotherapy. Two of them obtained results suppor-
ting the use of glutamine, though the samples sizes were 
relatively small (16-32 subjects)(19,20). In contrast, the 
study published by Pytlik et al. (18) not only found glu-
Table 1. Oral mucositis classification – staging system proposed by the 
World Health Organization (WHO).
Grade Clinical manifestations
0 No subjective or objective evidence of mucositis
I Pain with or without erythema, without ulcers
II Erythema and ulceration. The patient can swallow solids
III Erythema and ulceration. The patient can swallow liquids, 
but not solids
IV Erythema and ulceration. The patient cannot swallow liq-uids or solids
Oral mucositis causes many complications, ranging 
from speech and swallowing difficulties to intense pain 
and ulcer overinfection, which may lead to systemic 
infection (bacteremia or fungemia) – posing a threat to 
patient life and requiring admission to hospital, with the 
increased economic costs this implies. These complica-
tions may require reduction or even suspension of the 
antineoplastic treatment, with the risk of seriously wor-
sening the patient prognosis (3,5,9,10).
In relation to OM secondary to chemotherapy, many 
studies have evaluated the efficacy of different interven-
tions designed to prevent and/or treat the disease.
The present review examines those therapeutic tools 
that have been shown to be useful in the prevention or 
treatment of OM.
Material and Methods
A literature search was made of the PubMed, Cochrane 
and Scopus databases, using different combinations of 
the following key words: “oral mucositis”, “treatment”, 
“prevention”, “management”, “chemotherapy”. These 
key words in turn were validated by the “Mesh” and 
“DeCS” dictionaries, and the boolean operator “AND” 
was used to relate them in each search. The limits esta-
blished for inclusion of the articles in the study were: 
publications in English, studies in humans, and articles 
published over the last 10 years [2002-2012].
Following application of the filters, we identified 169 
articles. Many of them were discarded, since they only 
focused on OM associated to radiotherapy. We finally 
selected only those publications affording a scientific 
evidence level of I-II according to the classification 
proposed by the National Health and Medical Research 
Council of Australia (11), and those articles which while 
not constituting systematic reviews did specify the ma-
terial and methods used. A total of 44 articles were thus 
finally obtained. 
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al. (24) and Nikoletti et al. (25) conducted clinical trials 
in patients treated with 5-FU; Gori et al. (26) studied pa-
tients treated with methotrexate; and Lilleby et al. (27) 
and Svanberg et al. (28) investigated conditioning the-
rapies with melphalan prior to hematopoietic stem cell 
transplantation (HSCT). The results showed cryotherapy 
to be effective in the prevention of OM when used with 
chemotherapeutic agents having a short plasma half-life, 
such as bolus doses of 5-fluorouracil and melphalan. In 
contrast, drugs with a half-life of between 3-15 hours, 
such as methotrexate, yielded inconclusive results.
- Growth factors
Growth factors are proteins that stimulate cell growth, 
proliferation and differentiation. Within this family of 
proteins, the growth factors most widely investigated 
in the prevention and treatment of OM are palifermin 
(keratinocyte growth factor) and the colony-stimulating 
factors (29).
Palifermin (Kepivance®) is a recombinant human kera-
tinocyte growth factor that stimulates epithelial cell pro-
liferation and increases the thickness of the non-keratini-
zed layers of the oral and gastrointestinal mucosa (29). 
In this review we identified 8 RCCTs (Table 3) in which 
the efficacy of palifermin in the prevention of OM indu-
tamine to be ineffective in the prevention of OM, but 
also suggested that it might worsen OM and even increa-
se the risk of tumor relapse.
- Allopurinol
Allopurinol has been used on an experimental basis for 
both the prevention and treatment of mucositis induced 
by fluorouracil. Its activity is based on two different me-
chanisms: the elimination of ROS, and specific inhibi-
tion of the activation of fluorouracil.
The clinical trial conducted by Panahi et al. (21) found 
allopurinol rinses to offer little efficacy in preventing 
OM in patients subjected to chemotherapy with 5-FU.
- Cryotherapy
The application of ice within the oral cavity causes local 
vasoconstriction, which in turn lessens blood flow to the 
oral mucosa and reduces the amount of cytotoxic medi-
cation reaching the cells – thereby lowering the inciden-
ce of mucositis (22).
This technique involves placing ice cubes in the mouth 
5 minutes before starting the chemotherapy cycle, and 
keeping them in the mouth for 30-45 minutes.
Cryotherapy for the prevention of OM has been studied 
in application to different chemotherapy regimens (Ta-
ble 2). In this context, Sorensen et al. (23), Papadeas et 
Table 2. Studies on cryotherapy for the prevention of oral mucositis.
Author No. patients Drug (CT) Results
Sorensen et al. (23) 225 5-FU Effective
Papadeas et al. (24) 76 5-FU Effective
Nikoletti et al. (25) 67 5-FU Effective
Gori et al. (26) 130 Methotrexate Ineffective
Lilleby et al. (27) 40 Melphalan (conditioning prior to HSCT) Effective
Svanberg et al. (28) 80 Melfalan (conditioning prior to HSCT) Effective
* CT: chemotherapy; HSCT: hematopoietic stem cell transplantation
Author Palifermin 
dose
No. 
patients
Type of cancer Treatment Results
Meropol et al. 
(35) 2003 
1, 10, 20, 40, 60 
or 80 μg/kg/d
81 Metastatic colorectal 
cancer
CT Effective
Spielberger et 
al. (30) 2004
60 μg/kg/d 212 Lymphoma, leukemia 
or multiple myeloma
Conditioning (CT+RT) 
prior to autologous 
HSCT
Effective
Blazar et al. 
(31) 2006
40 or 60 μg/
kg/d
100 Lymphoma, leukemia 
or myelodysplastic 
syndrome
Conditioning (2 options):
A: CT+RT
B: CT
Prior to allogenic HSCT
Effective 
in patients 
with adju-
vant RT 
Rosen et al. 
(36) 2006
40 μg/kg/d 64 Solid tumors (colon 
and rectum)
CT Effective 
Brizel et al. 
(32) 2008
60 μg 99 Head and neck cancer RT+CT Ineffective
Vadhan-Raj et 
al. (37) 2010
180 μg/kg/d 48 Sarcoma CT Effective
Henke et al. 
(33) 2011
120 μg/kg/wk 186 Head and neck cancer RT+CT  Effective
Le et al. (34) 
2011
180 μg/kg/wk 188 Head and neck cancer RT+CT  Effective
*CT: chemotherapy; RT: radiotherapy; HSCT: hematopoietic stem cell transplantation
Table 3. Studies of palifermin in the prevention of oral mucositis.
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There have been no RCCTs in the last decade on the 
preventive or therapeutic efficacy of G-CSF in applica-
tion to mucositis. In relation to GM-CSF, the studies of 
Dazzi et al. (38) and Valcarcel et al. (39) indicate scant 
efficacy on the part of oral rinses containing GM-CSF in 
preventing and treating mucositis.
- Low-ievel laser therapy (LLLT)
It is known that radiation, at certain wavelengths, may 
exert beneficial effects upon cells. Phototherapy, inclu-
ding low-level laser therapy (LLLT), is based on the 
interaction of low energy density light (a few J/ cm2) 
with cells and tissues, without the generation of ther-
mal effects. It is believed that this type of therapy, with 
wavelengths of between 600-900 nm, could exert a bio-
modulating effect upon cells and tissues secondary to 
absorption of the light by endogenous photoreceptors 
(7,40). The activation of these photoreceptors may mo-
dify cell metabolism depending on the light energy dose 
delivered. Accordingly, low energy doses could act by 
reducing the production of ROS, and also by stimulating 
protein synthesis with the 
facilitation of tissue repair. Likewise, they may exert an 
antiinflammatory effect by reducing prostaglandin syn-
thesis (7).
In recent years different studies have been made on the 
use of LLLT for the prevention and treatment of oral mu-
cositis (Table 4).
The studies of Schubert et al. (41) and Antunes et al. (42) 
have demonstrated the efficacy of LLLT at wavelengths 
of 650-660 nm in the prevention of OM among patients 
subjected to conditioning with chemotherapy or chemo-
therapy - radiotherapy prior to HSCT.
However, the study published by Cruz et al. (43) revea-
led no benefits with the preventive use of LLLT in pa-
tients subjected to different chemotherapy regimens.
The results likewise have not been encouraging in pa-
tients with head and neck cancer scheduled for chemo-
therapy - radiotherapy (44).
In assessing the efficacy of LLLT in the treatment of es-
tablished mucositis, mention must be made of the studies 
ced by chemotherapy has been studied (30-37).
Although the results have been promising in almost all 
of these trials, the publication with the strongest me-
thodological design was that carried out by Spielberger 
et al. (30), who found palifermin to be very effective 
in the prevention of oral mucositis in patients schedu-
led for conditioning treatment (chemotherapy and total 
body irradiation) prior to hematopoietic stem cell trans-
plantation.
In contrast, the results obtained are not so good when 
the patients are subjected to conditioning treatment with 
chemotherapy but without total body irradiation prior to 
allogenic stem cell transplantation (31).
Regarding patients with head and neck cancer subjec-
ted to chemotherapy – radiotherapy, the results obtained 
by Brizel et al. (32) reveal no efficacy on the part of 
palifermin, in contrast to the data obtained by the stu-
dies published in 2011 by Henke et al. (33) and Le et 
al. (34), in which palifermin was seen to significantly 
reduce the incidence of severe OM. The explanation for 
these conflicting results may be the possibly insufficient 
palifermin dose (60 μg in a single dose) administered in 
the study of Brizel et al.
The studies published by Meropol et al. (35), Rosen et 
al. (36) and Vadhan-Raj et al. (37) support the efficacy of 
palifermin in patients with solid tumors (metastatic co-
lorectal cancer or sarcoma) subjected to chemotherapy, 
though it must be noted that their data may involve bias 
(masking difficulties, small sample size, etc.).
Colony-stimulating factors are glycoproteins produced 
by a broad range of human cells, some of which are of 
hematopoietic lineage, such as fibroblasts, endothelial 
cells and immune system cells (macrophages, T cells). 
Interest has focused mainly on granulocyte colony-sti-
mulating factor (G-CSF) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF). Both act at two 
levels in the prevention and treatment of mucositis: at 
central level by stimulating bone marrow recovery, and 
at peripheral level by promoting keratinocyte production 
(3,29).
Table 4. Studies of low-level laser therapy in the prevention and treatment of oral mucositis.
Author No. patients CT scheme Therapeutic objective Results
Schubert et al. (41) 70 Conditioning (CT and/
or RT) prior to HSCT
Prevention of OM Effective
Antunes et al. (42) 38 Conditioning (CT and/
or RT) prior to HSCT
Prevention of OM Effective
Cruz et al. (43) 60 CT Prevention of OM Ineffective
Gouvêa de Lima et 
al. (44)
75 CT+RT (head and 
neck cancer)
Prevention of OM Ineffective
Genot-Klastersky et 
al. (45)
36 Conditioning (CT) 
prior to HSCT
Treatment of OM Effective
Kuhn et al. (46) 21 Conditioning (CT and/
or RT) prior to HSCT
Treatment of OM Effective
*CT: chemotherapy; RT: radiotherapy; HSCT: hematopoietic stem cell transplantation
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carried out by Genot-Klastersky et al. (45) and Kuhn et 
al. (46). Both reported a clear decrease in the duration of 
OM in the patients treated with LLLT.
Discussion
On the basis of the data afforded by the reviewed stu-
dies, an analysis can be made of their conclusions, com-
paring them with those of other literature reviews and 
metaanalyses published over the last 10 years.
Worthington et al. (47) published a systematic review 
in the Cochrane database referred to randomized studies 
on the prevention of mucositis, with the inclusion of a 
total of 131 trials assessing 43 different interventions. 
Based on all these studies, the authors firstly concluded 
that only cryotherapy and palifermin offer some eviden-
ce of benefit. Secondly, very weak evidence of benefit 
was observed for 8 interventions (aloe vera, amifostine, 
glutamine, G-CSF, honey, laser, polymyxin / tobramycin 
/ amphotericin (PTA) paste or tablets, and sucralfate). 
On the other hand, they pointed out that all 10 interven-
tions were considered to imply a high or uncertain risk 
of bias.
Regarding the metaanalysis on the treatment of mucosi-
tis published by Clarkson et al. (48) in the same database, 
the authors found that of the 21 interventions included 
(32 trials), only LLLT showed a certain effectiveness in 
the treatment of mucositis, based on two studies with no 
high risk of bias in the results obtained.
It must be underscored that these reviews included inter-
ventions aimed at preventing and treating OM induced 
both by chemotherapy and radiotherapy, while our re-
view focused on the techniques used to prevent or treat 
mucositis induced only by chemotherapy or by combina-
tions of chemotherapy - radiotherapy. On the other hand, 
and since there are many chemotherapy regimens, we 
were interested in specifying not only which interven-
tions show some scientific evidence of efficacy, but also 
in application to which kind of chemotherapy regimen.
Of all the interventions analyzed in our review, only 
three showed significant efficacy in preventing OM (cr-
yotherapy, palifermin and LLLT), while only one inter-
vention proved effective in the treatment of established 
mucositis (LLLT).
Cryotherapy has been one of the most widely investiga-
ted interventions over the years. As we have seen, it is 
very effective in preventing OM in patients scheduled 
for chemotherapy with antineoplastic drugs that have 
a short plasma half-life, such as bolus doses of 5-fluo-
rouracil or the administration of high-dose melphalan 
prior to HSCT.
Another treatment supported by important scientific evi-
dence is palifermin (keratinocyte growth factor). Indeed, 
it is the only drug approved to date by the United States 
Food and Drug Administration (FDA) for the prevention 
of oral mucositis in patients subjected to myeloablative 
treatment with chemotherapy and radiotherapy prior to 
HSCT. The clinical trials show the ideal approach in pa-
tients of this kind to be the intravenous administration 
of 60 μg/kg of palifermin a day during three consecutive 
days before the start of conditioning, with a further three 
days of administration after stem cell transplantation 
(days 0, 1 and 2).
In 2011, the studies carried out by Henke et al. (33) 
and Le et al. (34) indicated that palifermin could also 
be effective for the prevention of OM in head and neck 
cancer patients subjected to radiotherapy (total dose 60-
66 Gy) together with chemotherapy (cisplatin). 
Interest in the development of radiation techniques for 
the prevention and treatment of OM has grown in recent 
years. To date, low-level laser therapy (LLLT) is the te-
chnique that has shown the greatest effectiveness. Many 
clinical trials have evaluated the preventive efficacy of 
LLLT, and the best results have been obtained when it 
is used in patients subjected to conditioning regimens 
prior to HSCT. 
According to the review published by Clarkson et al. 
(48), LLLT is the only technique to have shown certain 
evidence of efficacy in the treatment of established mu-
cositis. This is the conclusion drawn from the clinical 
trials carried out by Genot-Klastersky et al. (45) and 
Kuhn et al. (46), in which patients with OM secondary 
to conditioning prior to HSCT recovered earlier from 
their oral lesions when laser therapy was applied. Ne-
vertheless, it must be underscored that these are only 
two studies, and moreover involve few patients (57 in 
total). The body of evidence for this type of intervention 
is therefore smaller than in the above cases.
It is also important to emphasize the importance of co-
rrect oral hygiene in cancer patients. Although there is 
no scientific evidence demonstrating the efficacy of oral 
hygiene protocols in the prevention and treatment of 
mucositis, the great majority of authors agree that ad-
hesion to oral hygiene measures can reduce the dura-
tion and severity of OM (12), as well as help prevent 
the development of dental problems during the cancer 
treatment cycles.
The rest of the interventions showed no evidence of be-
nefit, either due to methodological shortcomings of the 
trials, or because of contradicting results.
Our conclusions coincide with the guidelines the Mul-
tinational Association of Supportive Care in Cancer 
(MASCC) and the International Society of Oral Oncolo-
gy (ISOO), which were updated in 2012 through several 
review articles (15,22,29,40).
In sum, at present no concrete intervention may be re-
garded as the gold standard for the prevention and/
or treatment of oral mucositis, and we therefore must 
resort to recommendations based on the documented 
evidence. This indicates the need for increasing the me-
thodological quality and number of clinical trials with 
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the aim of expanding the scientific evidence supporting 
the different interventions. In this context, clinical trials 
should be carried out following the norms established by 
the CONSORT (Consolidated Standards of Reporting 
Trials) declaration, and including sufficient patients and 
subgroups in accordance to the type of chemotherapeutic 
agent involved. On the other hand, we consider it very 
important to unify criteria regarding the use of a single 
mucositis severity grading system, since this would fa-
cilitate comparisons among the different studies. In this 
respect, we recommend use of the scale developed by 
the WHO (grades 0-4) (Table 1).
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